Developing partnerships and collaborations is a key part of our strategy to successfully leverage our proprietary drug delivery system to bring more effective treatments to urology and oncology patients with unmet needs. If you are interested in partnering with us please contact our Corporate Development team at corpdev@lipaconcology.com.

In September 2019, LIPAC entered into an exclusive licensing agreement with Huons Co. to develop, manufacture and commercialize TBC-1002 for Non-Muscle Invasive Bladder Cancer and other related indications in Korea. The transaction included an upfront payment, future milestone payments and ongoing royalties to LIPAC based on specific development, regulatory and commercial milestones. Click here to read more.